The Case for Gross-to-Net Automation

September 15, 2021 | OnDemand

As the GTN bubble grows, so does increased stakeholder scrutiny on GTN analytics. Although the industry is moving toward automating GTN processes, many life sciences manufacturers are not embracing automation at pace with the industry and often face obstacles in achieving their automation goals.

In this informative webinar, Jen Sharpe, GTN lead and facilitator of the Revenue Analytics Collaborative at IntegriChain reviews the results of the recent GTN Automation survey and report, discusses the value of automation, and the best ways to build a business case within the organization.

Topics covered include:

  • Who has embraced GTN automation
  • How to identify and mitigate barriers to adoption that exist in the industry
  • What current or potential risks currently exist around automation
  • How to transform risks into successful outcomes

jen sharpe

Jen Sharpe

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article